(Image source from: Canva.com)

As we approach the end of 2025, it is evident that the field of cancer treatment is undergoing significant changes due to new ideas and technologies. The speed of advancements, ranging from new medications and cell therapies to the integration of technology and patient-focused care models, seems quicker than in recent times. In India, where cancer cases are increasing, these developments are especially important, as they not only aim for better survival rates but also strive to provide more accessible and tailored treatments. Here is my brief view, supported by evidence, highlighting the key advancements of 2025 and what they mean for cancer treatment in India.

Expanding Success in Targeted Treatments: One of the major achievements this year is the growth of targeted treatments into new primary roles. A notable instance is the approval of Antibody Drug Conjugates by the FDA for first-line treatment of advanced HER2-positive breast cancer, which shows marked improvements in survival without disease progression and high rates of tumor responses. For cancer doctors in India, this development indicates a significant shift: focusing on precise treatment based on individual molecular profiles is becoming the norm, rather than relying solely on general chemotherapy. This highlights the need to enhance genetic testing and biomarker evaluations in Indian healthcare facilities.

Advances in Immunotherapy and Cell Therapy: Immunotherapy remains at the forefront of cancer treatment breakthroughs in 2025. Checkpoint inhibitors have broadened their uses to include treatments before and after surgery for advanced head and neck cancers, supported by strong evidence from key studies. CAR-T cell therapies are continuing to progress, with India achieving historic advancements with local CAR-T products like Qartemi and NexCAR19, providing top-quality results at much lower costs compared to Western treatments, which is crucial for affordability. Beyond CAR-T therapies, there is also growing interest in CAR-NK cells, a new type of ready-to-use immunotherapy that may have reduced side effects and simpler logistics, though it is still in the early stages of clinical use. These innovations reinforce a worldwide shift: using the immune system in cancer care is no longer just experimental but has become a vital part of standard treatment for various cancers.

Innovations in Oral and Systemic Medications: In 2025, we have also seen significant improvements in systemic therapies. A new type of SERD for hormone-receptor positive breast cancer has decreased the chance of the disease returning by about 30% in a crucial trial, potentially reshaping the standards for hormone-based treatments. Fast-track review incentives for new combinations for blood cancers, like bispecific T-cell engagers paired with CD38-directed antibodies in multiple myeloma, showcase the ongoing progress in blood-related cancers. These advances in medication emphasize that our range of available treatments is growing and becoming more sophisticated, allowing for longer disease control while being easier for patients to tolerate.

AI, Genomics & Precision Medicine Integration: In 2025, the field of cancer treatment is closely linked to artificial intelligence and genomics. AI-based systems are speeding up the process of identifying cancers early, assessing risks, and choosing treatments, which makes personalized cancer care more achievable even in areas that lack specialized pathology or radiology services. Real-time genetic analysis along with AI tools for treatment decisions are starting to help in making difficult treatment choices, and this is a hopeful development for India’s varied patient groups. These advancements could greatly change the situation in India if improvements are made in digital infrastructure and training programs.

Radiopharmaceuticals & Precision Radiotherapy: Although not widely used in India yet, the global growth of radiopharmaceuticals, particularly those using alpha emitters for both diagnosis and treatment, is significant. Drugs that target PSMA or neuroendocrine cancers are proving to be more effective while causing fewer side effects. At the same time, radiation technology is advancing, with precise methods like proton therapy beginning to be used in some Indian medical centers, which enhances treatment effectiveness, particularly for cancers in the head and neck, children, and those at the base of the skull.

India's Strategic Initiatives and Accessibility Imperatives: In addition to scientific progress, 2025 brought important structural changes. The government is aiming to increase cancer daycare centers, improve the availability of essential drugs by lowering taxes on lifesaving medicines, and integrate cancer treatment into broader healthcare systems. However, cost remains a major issue. Unlike other countries that have organized systems for reimbursing cancer medications, India does not have a comprehensive coverage plan for new drugs, which limits access to expensive targeted and immunotherapies. Tackling this issue is as important as scientific progress to ensure that advances in treatment translate into better survival rates for the population.

In 2025, advancements in cancer care have made significant strides such as targeted therapies, immunotherapy, precise diagnostic techniques, AI-based decision-making assistance, as well as new radiation and cellular technologies. For India, the goal is to implement these innovations through evidence-based practices and to guarantee fair access through changes in policy and strengthening healthcare capacity. For oncologists, this time presents great opportunities—not only to prolong life but also to make treatments more accurate, manageable, and specifically suited to each patient’s unique biology and situation. The next challenge will be to ensure these breakthroughs are available in real clinical settings for all patients throughout our diverse healthcare system.